NEW TRANSCRIPTOMICA SIGNATURE MARKERS AND DEVELOPMENT OF A BIOINFORMATICS PIPELINE FOR THE PREDICTION OF ENDOMETRIAL RECEPTIVITY BY SEQUENCING (Q3249681): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the infer coords bot - inferring coordinates from location) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
NEW TRANSCRIPTOMICA SIGNATURE MARKERS AND DEVELOPMENT OF A BIOINFORMATICS PIPELINE FOR THE PREDICTION OF ENDOMETRIAL RECEPTIVITY BY SEQUENCING | |||
Revision as of 11:41, 12 October 2021
Project Q3249681 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEW TRANSCRIPTOMICA SIGNATURE MARKERS AND DEVELOPMENT OF A BIOINFORMATICS PIPELINE FOR THE PREDICTION OF ENDOMETRIAL RECEPTIVITY BY SEQUENCING |
Project Q3249681 in Spain |
Statements
1,500.0 Euro
0 references
3,000.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 December 2018
0 references
IGENOMIX, S.L.
0 references
39°30'14.11"N, 0°26'31.56"W
0 references
46190
0 references
Actualmente los test que se aplican para evaluar la receptividad del endometrio se están realizando con microarrays, y hasta la fecha no existe en el mercado ningún test equiparable en cuanto a eficacia al test ERA. Este análisis evalúa la expresión de 238 genes que han demostrado ser potenciales predictores transcriptómicos de la receptividad endometrial, permitiendo la identificación de la ventana de implantación (WOI) para cada paciente de forma personalizada. Las técnicas de microarray han permitido estudiar de forma específica los patrones de expresión génicos de la ventana de implantación y del resto de fases del ciclo menstrual. Así, el test ERA realizado a partir de tejido endometrial nos permite evaluar el estado receptivo de un endometrio en función de dichos patrones génicos. Sin embargo, diferentes mujeres pueden tener diferentes perfiles transcriptómicos incluso si las muestras se toman el mismo día o después del mismo régimen de tratamiento hormonal. Para solventar est (Spanish)
0 references
Currently, the test applied to assess endometrial receptivity are being made with microarrays, and to date there is no comparable market test for efficacy to test ERA. This analysis evaluates the expression of 238 genes that have proven transcriptome potential predictors of endometrial receptivity, allowing the identification of the window of implantation (WOI) for each patient in a personalized manner. Microarray techniques have allowed to study specifically patterns of gene expression of the implantation window and the other phases of the menstrual cycle. Thus, the test was accomplished from endometrial tissue allows us to evaluate the state receptive endometrium function of said gene patterns. However, different women may have different transcriptomic profiles even if the samples are taken on the same day or after the hormonal treatment regimen. To overcome these limitations, firstly that a more detailed report on the use of transcriptome predictors endometrial study, which will pro (English)
0 references
Paterna
0 references
Identifiers
20F01020101U_IVCI00000ACPA8241
0 references